Shares of clinical-stage biopharmaceutical company Gossamer Bio (NASDAQ:GOSS) are tanking today after the company announced the results of a Phase 2 study evaluating its product candidate seralutinib for the treatment of pulmonary arterial hypertension (PAH).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
While the trial met its primary endpoint, there was one serious adverse event as compared to zero events in the placebo arm of the study.
Shares of the company have now tanked nearly 78% over the past month while the Street has a Strong Buy consensus rating on GOSS alongside an average price target of $18.33.
Read full Disclosure